Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

被引：8

作者：

Bosanquet, N ^{[1
]}

Yeates, A

机构：

[1] Imperial Coll Sch Med, London, England

[2] Eisai Europe Ltd, London, England

来源：

PHARMACOECONOMICS | 2006年 / 24卷 / 06期

关键词：

D O I：

10.2165/00019053-200624060-00008

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：623 / 625

页数：3

共 50 条

[21] Cholinesterase inhibitors for Alzheimer's disease
Stahl, SM
HOSPITAL PRACTICE, 1998, 33 (11): : 131 - 136
[22] Cholinesterase inhibitors for Alzheimer's disease
Birks, J
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
[23] Cholinesterase inhibitors and Alzheimer's disease
Euba, Rafael
PSYCHIATRIC BULLETIN, 2006, 30 (02): : 76 - 76
[24] Cholinesterase inhibitors for Alzheimer's disease
Grutzendler, J
Morris, JC
DRUGS, 2001, 61 (01) : 41 - 52
[25] Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s DiseaseA Markov Model in Finland
Clément François
Harri Sintonen
Raimo Sulkava
Benoît Rive
Clinical Drug Investigation, 2004, 24 : 373 - 384
[26] Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer's Disease in the United States: A Cost-Effectiveness Analysis
Yunusa, Ismaeel
Alsahali, Saud
Ranes, Amey
Eguale, Tewodros
JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2021, 5 (01) : 705 - 713
[27] Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer’s DiseaseA Review with Methodological Considerations
Anders Wimo
Drugs & Aging, 2004, 21 : 279 - 295
[28] Cholinesterase Inhibitors in Alzheimer’s DiseaseAre they Worth the Cost?
Peter J. Whitehouse
CNS Drugs, 1999, 11 : 167 - 173
[29] Cholinesterase Inhibitors: Cardioprotection in Alzheimer's Disease
Monacelli, Fiammetta
Rosa, Gianmarco
JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (04) : 1071 - 1077
[30] A review on cholinesterase inhibitors for Alzheimer's disease
Anand, Preet
Singh, Baldev
ARCHIVES OF PHARMACAL RESEARCH, 2013, 36 (04) : 375 - 399

← 1 2 3 4 5 →